TNXP
Tonix Pharmaceuticals Holding Corp.
stockNASDAQ
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 9.90 | 2026-09-28 | -9.90% | -3.187 |
| 1M | 13.14 | 2026-09-04 | -32.12% | -0.437 |
| 3M | 12.71 | 2026-07-06 | -29.82% | 1.501 |
| 6M | 13.61 | 2026-04-06 | -34.46% | 1.318 |
| 1Y | 24.00 | 2025-10-03 | -62.83% | 1.914 |
| 2Y | 13.94 | 2024-10-04 | -36.01% | — |
| 5Y | 366,720.00 | 2021-10-04 | -100.00% | 1.266 |
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) stock price today is $8.92, and today's volume is 803,104. TNXP is down 3.359% today. The 30 day average volume is 473,847. TNXP market cap is $152.99M with 17.15M shares outstanding.